Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season (U18)

The summary for the Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season (U18) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season (U18)
	CFDA Number:	93.185
	CFDA Description:	Immunization Research, Demonstration, Public Information and Education_Training and Clinical Skills Improvement Projects
	Federal Agency Name:	Centers for Disease Control and Prevention
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-IP-10-007
	Document Type:	Grants Notice
	Funding Instrument Type:	Cooperative Agreement
	Posted Date:	Mar 01, 2010
	Creation Date:	Mar 01, 2010
	Original Closing Date for Applications:	Apr 26, 2010 Letter of Intent Receipt Date: March 29, 2010 Application Submission Receipt Date: April 26, 2010
	Current Closing Date for Applications:	Apr 26, 2010 Letter of Intent Receipt Date: March 29, 2010 Application Submission Receipt Date: April 26, 2010
	Archive Date:	May 26, 2010
	Expected Number of Awards:	2
	Estimated Total Program Funding:	$1,500,000
	Federal Grant Award Ceiling:	$1,000,000
	Federal Grant Award Floor:	$0
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Eligible Institutions You may submit an application(s) if your organization has any of the following characteristics: Public nonprofit organizations Private nonprofit organizations Universities Colleges Research institutions Hospitals Community-based organizations Faith-based organizations Federally recognized or state-recognized American Indian/Alaska Native tribal governments American Indian/Alaska Native tribally designated organizations Alaska Native health corporations Urban Indian health organizations Tribal epidemiology centers State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) Political subdivisions of States (in consultation with States) Foreign Institutions A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If you are applying as a bona fide agent of a state or local government, you must provide a letter from the state or local government as documentation of your status. Attach this documentation behind the first page of your application form or for electronic applications, use a PDF file and attach as "Other Documents" and label as appropriate.
Grant Description: Current adult community acquired pneumonia (CAP) treatment guidelines recommend empiric broad-spectrum antibiotics that are effective against common bacterial agents. The initiation of antibiotics does not require laboratory confirmation of a bacterial etiology but is based upon data from published CAP etiology studies. Despite studies that have identified influenza as an important etiological agent of adult hospitalized patients with CAP, especially during peak influenza circulation, anti-influenza antiviral agents are uncommonly used empirically for CAP. In addition, novel influenza A (H1N1) has been documented to cause primary viral pneumonia in a majority of deaths with extensive testing of autopsy specimens. Most clinicians wait for laboratory confirmation of influenza infection before considering antiviral therapy. However, in routine clinical practice, diagnostic testing for influenza is uncommon, commonly used rapid testing methods have low sensitivity, and more sensitive diagnostic assays such as RT-PCR are not readily available. Also, even influenza RT-PCR assays performed on respiratory specimens are not always optimal for the detection of influenza infection and results of testing may take several days, after which the benefit if initiating antivirals goes down since the medications are of greatest benefit the earlier they are initiated after illness onset from influenza. Studies in Thailand have demonstrated that an additional 10-20% of acute influenza cases were identified with serologic assays, in addition to RT-PCR techniques on nasopharyngeal specimens.Thus, the use of empiric antiviral therapy, in addition to empiric antibiotic therapy, may be warranted, especially during a period when influenza viruses are circulating in the community.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: CDC Procurement and Grants Office TIMS Phone 770-488-2700

PGOTIM@cdc.gov [PGOTIM@cdc.gov]
Similar Government Grants: • Addressing Immunization Disparities in Minority Populations; • Immunization Strengthening through Measles Control and Related Childhood Morbidity/Mortality Reducti...; • Developing and Disseminating Targeted Immunization Materials; • Integrated Economic, Dynamic Disease, Risk and Decision Analytic Modeling of Global and Domestic Pol...; • Strategies to Increase Health Care Providers Use of Population-Based Immunization Information System...; • Coordination of Activities Between the CDC's National Immunization Program and the State and Ter...; • National Minority Organizations Immunization Projects; • Using Provider Partnerships to Strengthen the Immunization Message; • Coordination of Activities Between the CDC, National Immunization Program and State and Local Immuni...; • Active Surveillance for Pertussis